We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Wall Street's Insights Into Key Metrics Ahead of Danaher (DHR) Q3 Earnings
Read MoreHide Full Article
Analysts on Wall Street project that Danaher (DHR - Free Report) will announce quarterly earnings of $1.72 per share in its forthcoming report, representing an increase of 0.6% year over year. Revenues are projected to reach $6 billion, increasing 3.4% from the same quarter last year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Danaher metrics that are routinely monitored and predicted by Wall Street analysts.
According to the collective judgment of analysts, 'Total sales- Diagnostics' should come in at $2.39 billion. The estimate points to a change of +1.2% from the year-ago quarter.
The consensus estimate for 'Total sales- Life Sciences' stands at $1.81 billion. The estimate suggests a change of +1.7% year over year.
It is projected by analysts that the 'Total sales- Biotechnology' will reach $1.78 billion. The estimate indicates a year-over-year change of +7.9%.
Analysts' assessment points toward 'Operating profit- Life Sciences' reaching $165.00 million. The estimate compares to the year-ago value of $35.00 million.
Analysts expect 'Operating profit- Biotechnology' to come in at $443.32 million. The estimate is in contrast to the year-ago figure of $390.00 million.
The combined assessment of analysts suggests that 'Operating profit- Diagnostics' will likely reach $546.66 million. The estimate compares to the year-ago value of $615.00 million.
Shares of Danaher have demonstrated returns of +6.8% over the past month compared to the Zacks S&P 500 composite's +0.9% change. With a Zacks Rank #4 (Sell), DHR is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Wall Street's Insights Into Key Metrics Ahead of Danaher (DHR) Q3 Earnings
Analysts on Wall Street project that Danaher (DHR - Free Report) will announce quarterly earnings of $1.72 per share in its forthcoming report, representing an increase of 0.6% year over year. Revenues are projected to reach $6 billion, increasing 3.4% from the same quarter last year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Danaher metrics that are routinely monitored and predicted by Wall Street analysts.
According to the collective judgment of analysts, 'Total sales- Diagnostics' should come in at $2.39 billion. The estimate points to a change of +1.2% from the year-ago quarter.
The consensus estimate for 'Total sales- Life Sciences' stands at $1.81 billion. The estimate suggests a change of +1.7% year over year.
It is projected by analysts that the 'Total sales- Biotechnology' will reach $1.78 billion. The estimate indicates a year-over-year change of +7.9%.
Analysts' assessment points toward 'Operating profit- Life Sciences' reaching $165.00 million. The estimate compares to the year-ago value of $35.00 million.
Analysts expect 'Operating profit- Biotechnology' to come in at $443.32 million. The estimate is in contrast to the year-ago figure of $390.00 million.
The combined assessment of analysts suggests that 'Operating profit- Diagnostics' will likely reach $546.66 million. The estimate compares to the year-ago value of $615.00 million.
View all Key Company Metrics for Danaher here>>>Shares of Danaher have demonstrated returns of +6.8% over the past month compared to the Zacks S&P 500 composite's +0.9% change. With a Zacks Rank #4 (Sell), DHR is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .